Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors.

Complement inhibitors are now approved for use in atypical hemolytic uremic syndrome, IgA nephropathy, and C3 glomerulopathy. They are being studied widely in kidney disease, and more indications may soon arise. This review addresses an approach to p…

Preview only. Read the full abstract at the source